Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis
The increased rate of coccidioidomycosis-associated deaths observed among men might reflect their higher risk for severe pulmonary and disseminated coccidioidomycosis
An estimated 1% of all infections, asymptomatic and symptomatic, progress to extrathoracic disseminated coccidioidomycosis
infection (3,4), which is more common among persons with underlying immune conditions, such as advanced HIV/AIDS.
typically involves the skin, meninges, or bone (3); however, intraocular involvement has also been described (1).
We can argue that the recipients may have been infected independent of their receipt of organ transplant, and subsequently, disseminated coccidioidomycosis
developed after transplant-associated immunosuppressive therapy.
After the diagnosis of disseminated coccidioidomycosis
(pneumonia, fungemia, and meningitis), voriconazole was replaced by intravenous fluconazole, 400 mg/day.
Vaccination of adults to prevent disseminated coccidioidomycosis
would provide a modest health benefit similar in magnitude to other vaccines but would increase net expenditures.
Participants included African-American, Caucasian, and Hispanic persons with mild or severe disseminated coccidioidomycosis
from Kern County, California.
Severe or disseminated coccidioidomycosis
requires treatment and can be fatal.
Persons with acute or disseminated coccidioidomycosis
may not develop a delayed-type hypersensitivity response to SPHERUSOL.
A few patients develop disseminated coccidioidomycosis
, which is associated with high morbidity and mortality.
A 27-year-old gravida 3, para 2 pregnant woman was hospitalized at our institution at 26 weeks for disseminated coccidioidomycosis
including diffuse pulmonary infiltrates and a lytic bone lesion in her iliac crest.